Efficacy and Safety of DPP-4 Inhibitors and Metformin Combinations in Type 2 Diabetes: A Systematic Literature Review and Network Meta-Analysis
DOI: https://doi.org/10.2147/dmso.s450994
2024-06-19
Diabetes Metabolic Syndrome and Obesity Targets and Therapy
Abstract:Rongping Chen, 1, &ast Jing Li, 2, &ast Danqi Chen, 3, &ast Weiheng Wen, 1 Susu Zhang, 1 Jitong Li, 1 Yuting Ruan, 1 Zhen Zhang, 1 Jia Sun, 1 Hong Chen 1 1 Department of Endocrinology, Zhujiang Hospital, Southern Medical University, Guangzhou, People's Republic of China; 2 Department of Endocrinology, HuaZhong University of Science and Technology Union ShenZhen Hospital, Guangdong, People's Republic of China; 3 Institute for Prevention and Control of Chronic Noncommunicable Diseases, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, People's Republic of China &astThese authors contributed equally to this work Correspondence: Hong Chen; Jia Sun, Department of Endocrinology, Zhujiang Hospital, Southern Medical University, Guangzhou, People's Republic of China, Email ; Objective: Several oral antidiabetic regimens are available for treating type 2 diabetes mellitus (T2DM), dipeptidyl peptidase-4 inhibitors (DPP4i) being one of them. We conducted a network meta-analysis (NMA) comparing DPP4i plus metformin (Met) combination with other Met-based oral antidiabetic drug (OAD) combinations used in treating patients with T2DM. Methods: We searched PubMed and Embase from inception until 19th April, 2022 for phase II and phase III trials in patients with T2DM on Met-based traditional OADs. The primary outcome was assessed by change in glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), and 2-hour post-prandial blood glucose (2h-PPG). The secondary safety outcomes assessed were hypoglycemic events, serious adverse events (SAEs), cardiovascular (CV) events, and gastrointestinal (GI) events. Results: Sixty-two trials were included in the analysis. The combination of DPP4i + Met revealed a comparable mean reduction in HbA1c levels to the glinides (Gli) + Met combination (mean difference [MD]: − 0.03%, 95% CI: 0.69, − 0.65), although the difference was not statistically significant. The mean HbA1c reduction with DPP4i + Met was greater than with sulfonylureas (SU) + Met (MD: − 0.05, 95% CI: − 0.29, 0.39), thiazolidinedione (TZD) + Met (MD: − 0.69, 95% CI: − 1.39, − 0.02), and SU + TZD (MD: 0.21; 95% CI: − 1.30, 1.71), with no statistical significance. DPP4i + Met demonstrated a non-significant lower incidence of CV events in comparison to TZD + Met (RR: 1.01, 95% CI: 0.46, 2.45) and SU + Met (RR: 1.06, 95% CI: 0.61, 2.06). Conclusion: DPP4i in combination with Met was efficacious and had a well-tolerated safety profile compared with other traditional OADs. This combination can be considered as a suitable treatment option for patients with T2DM. Keywords: dipeptidyl peptidase-4 inhibitors, efficacy, safety, metformin, type 2 diabetes mellitus Diabetes mellitus (DM) is an endocrine metabolic disease characterized by the presence of hyperglycemia. 1 About 537 million adults are currently living with the burden of diabetes, and this is expected to rise to 643 million by 2030 and 783 million subsequently. 2 In recent, the incidence of type 2 diabetes mellitus (T2DM) in developing countries has substantially escalated, posing a huge burden on the economy. 3 To reduce long-term complications, most patients are recommended glucose-lowering oral antidiabetic drugs (OADs). The American Diabetes Association (ADA) states that first-line therapy for diabetes management usually involves metformin (Met), along with comprehensive lifestyle modification. Based upon a patient's glycemic needs, agents such as sodium–glucose co-transporter 2 (SGLT2) inhibitor or a glucagon-like peptide-1 receptor agonist (GLP-1RA) with or without Met are recommended as initial therapy in patients with T2DM or who have a high risk for atherosclerotic cardiovascular (ASCV) disease, heart failure, and/or chronic kidney disease. 4 The efficacy of Met has been extensively studied, often in comparison with other drugs already in use. In short- and medium-term therapies, Met has shown efficacy comparable to sulfonylureas, mitigating the hypoglycemic risks. Moreover, it has demonstrated higher efficacy compared to dipeptidyl peptidase-4 inhibitors (DPP4i), but lower efficacy than that of glucagon-like peptide-1 (GLP-1) receptor agonists. In the context of long-term monotherapy, Met has shown increased efficacy compared to sulfonylureas. 5 Besides, SGLT2 inhibitors or GLP-1RA are also recommended in patients with established ASCV, kidney disease, or heart failure, considering patient-related factors and independent of glycemic levels. 4 However, many patients, particularly those with higher baseline glycated h -Abstract Truncated-
endocrinology & metabolism